Age-associated defect in ADCC response to COVID-19 vaccine.

Publication date: Jul 01, 2025

We investigated age-associated effects of SARS-CoV-2 vaccination in elderly individuals (n = 50, mean age 79) after six SARS-CoV-2 vaccine doses. While neutralization titers remained comparable across age groups, Fc-mediated effector functions declined with age. Individuals >80 demonstrated reduced antibody-dependent cellular cytotoxicity (ADCC), via a surrogate ADCC-signaling assay, correlating with diminished IgG1 binding. These findings highlight age-related impairments in Fc-mediated responses, with implications for immune protection and vaccine strategies in older populations.

Open Access PDF

Concepts	Keywords
Covid	Adcc
Cytotoxicity	Age
Elderly	Associated
Vaccination	Cov
	Covid
	Defect
	Elderly
	Fc
	Individuals
	Investigated
	Mediated
	Sars
	Vaccination
	Vaccine
	Vaccines

Semantics

Type	Source	Name
disease	IDO	assay
disease	MESH	COVID 19
pathway	REACTOME	Immune System
disease	MESH	viral infections
disease	MESH	influenza
disease	IDO	protein
disease	IDO	blood
disease	MESH	Allergy
disease	MESH	Infectious Diseases
disease	MESH	infection
drug	DRUGBANK	Proline
pathway	KEGG	Virion
disease	IDO	production
drug	DRUGBANK	Coenzyme M
disease	MESH	defects
disease	IDO	susceptibility
disease	MESH	breakthrough infections
drug	DRUGBANK	Isoxaflutole
disease	IDO	quality
disease	MESH	inflammation
disease	IDO	replication
disease	IDO	host
disease	IDO	reagent
drug	DRUGBANK	Streptomycin
disease	IDO	cell
drug	DRUGBANK	Arbutin
disease	MESH	death
disease	MESH	vasculitis
disease	MESH	respiratory syncytial virus infection
pathway	REACTOME	Influenza Infection
disease	MESH	tetanus
disease	MESH	Causes
disease	MESH	clonal hematopoiesis
disease	MESH	malignancy
disease	MESH	chronic lymphocytic leukemia
disease	MESH	Leukemia
disease	MESH	melanoma
pathway	KEGG	Melanoma
disease	MESH	clinical relevance
disease	MESH	autoimmune diseases
disease	IDO	nucleic acid
pathway	REACTOME	Reproduction

Original Article

(Visited 2 times, 1 visits today)